文献速递产科母胎医学

联合胎儿生物测量与母体生物标志物筛查胎儿生长受限

Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers.
PubMed 文献 · Am J Obstet Gynecol · 2017-12-22

胎儿生长受限是围产期病残和死亡的主要决定因素,但筛查困难。美国与英国以临床风险评估结合高危孕妇超声筛查为标准,敏感性低;随机对照试验系统综述未显示孕晚期普遍超声筛查获益,证据不强。法国低危孕妇普遍超声筛查未降低小于胎龄儿并发症风险,却对假阳性造成医源性伤害。作者提出联合胎儿生物测量与胎盘功能障碍血液标志物以提高筛查特异性。

要点

  • 临床风险评估结合高危孕妇超声筛查是美国和英国的标准,但敏感性低。
  • 随机对照试验系统综述未显示孕晚期普遍超声筛查胎儿生长受限的获益,证据不强。
  • 法国低危孕妇普遍超声筛查未降低小于胎龄儿并发症风险,却对假阳性造成医源性伤害。

核心结论

  • 提高筛查敏感性和特异性以区分健康小胎儿与胎儿生长受限是关键目标。
  • 联合胎儿生物测量与胎盘功能障碍血液标志物是有前景的策略。
  • 组学技术有望发现新标志物,但需解决方法学问题并开发疾病修饰干预。

研究设计与样本

  • 本文为综述,讨论胎儿生长受限筛查策略,未报告系统检索范围。
  • 涉及临床风险评估结合高危孕妇超声筛查、普遍超声筛查随机对照试验系统综述及法国低危孕妇普遍超声筛查的实施经验。

主要发现

  • 临床风险评估结合高危孕妇超声筛查是美国和英国的标准,但敏感性低。
  • 随机对照试验系统综述未显示孕晚期普遍超声筛查胎儿生长受限的获益,证据不强。
  • 法国低危孕妇普遍超声筛查未降低小于胎龄儿并发症风险,却对假阳性造成医源性伤害。
  • 妊娠相关血浆蛋白A主要评估唐氏综合征风险,孕早期低水平与胎盘所致死产包括胎儿生长受限相关,故孕晚期连续超声监测。
  • 既往胎盘功能障碍指标多为超声测量如子宫胎盘循环多普勒血流速度测量。

关键数值与推荐

  • 美国与英国以临床风险评估结合高危孕妇超声筛查为标准。
  • 随机对照试验系统综述未显示孕晚期普遍超声筛查胎儿生长受限的获益,证据不强。
  • 法国低危孕妇普遍超声筛查未降低小于胎龄儿并发症风险,却对假阳性造成医源性伤害。

临床怎么用

  • 美国与英国以临床风险评估结合高危孕妇超声筛查为标准。
  • 作者提出联合胎儿生物测量与胎盘功能障碍血液标志物以提高筛查特异性。
  • 作者希望组学标志物联合超声胎儿生物测量对胎儿生长受限及相关并发症有强预测力。

局限性

  • 临床风险评估结合高危孕妇超声筛查的敏感性低。
  • 随机对照试验系统综述未显示孕晚期普遍超声筛查胎儿生长受限的获益,证据不强。
  • 法国低危孕妇普遍超声筛查未降低小于胎龄儿并发症风险,却对假阳性造成医源性伤害。
  • 许多母体血清标志物研究为对其他指征检测的二次分析,如胎儿非整倍体。
  • 评估新检测诊断效度需解决一系列重要方法学问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal growth restriction is a major determinant of perinatal morbidity and mortality. Screening for fetal growth restriction is a key element of prenatal care but it is recognized to be problematic. Screening using clinical risk assessment and targeting ultrasound to high-risk women is the standard of care in the United States and United Kingdom, but the approach is known to have low sensitivity. Systematic reviews of randomized controlled trials do not demonstrate any benefit from universal ultrasound screening for fetal growth restriction in the third trimester, but the evidence base is not strong. Implementation of universal ultrasound screening in low-risk women in France failed to reduce the risk of complications among small-for-gestational-age infants but did appear to cause iatrogenic harm to false positives. One strategy to making progress is to improve screening by developing more sensitive and specific tests with the key goal of differentiating between healthy small fetuses and those that are small through fetal growth restriction. As abnormal placentation is thought to be the major cause of fetal growth restriction, one approach is to combine fetal biometry with an indicator of placental dysfunction. In the past, these indicators were generally ultrasonic measurements, such as Doppler flow velocimetry of the uteroplacental circulation. However, another promising approach is to combine ultrasonic suspicion of small-for-gestational-age infant with a blood test indicating placental dysfunction. Thus far, much of the research on maternal serum biomarkers for fetal growth restriction has involved the secondary analysis of tests performed for other indications, such as fetal aneuploidies. An exemplar of this is pregnancy-associated plasma protein A. This blood test is performed primarily to assess the risk of Down syndrome, but women with low first-trimester levels are now serially scanned in later pregnancy due to associations with placental causes of stillbirth, including fetal growth restriction. The development of "omic" technologies presents a huge opportunity to identify novel biomarkers for fetal growth restriction. The hope is that when such markers are measured alongside ultrasonic fetal biometry, the combination would have strong predictive power for fetal growth restriction and its related complications. However, a series of important methodological considerations in assessing the diagnostic effectiveness of new tests will have to be addressed. The challenge thereafter will be to identify novel disease-modifying interventions, which are the essential partner to an effective screening test to achieve clinically effective population-based screening.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gaccioli F, Aye ILMH, Sovio U, et al. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2017. PMID: 29275822. doi:10.1016/j.ajog.2017.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。